INDV
Indivior Pharmaceuticals Inc NASDAQ Listed Dec 29, 2014$38.30
+0.98%
vs $37.93
Mkt Cap $4.8B
52w Low $13.45
90.2% of range
52w High $41.00
50d MA $36.20
200d MA $32.03
P/E (TTM)
23.4x
EV/EBITDA
16.4x
P/B
—
Debt/Equity
-3.6x
ROE
-214.3%
P/FCF
-52.7x
RSI (14)
63.00
ATR (14)
$1.30
Beta
1.21
50d MA
$36.20
200d MA
$32.03
Avg Volume
1.9M
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
10710 Midlothian Turnpike · North Chesterfield, VA 23235 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | 0.64 | 0.96 | +50.0% | 34.15 | +5.3% | +7.7% | +2.4% | +3.5% | +1.6% | +2.6% | — |
| Feb 26, 2026 | BMO | 0.65 | 0.82 | +26.2% | 33.63 | +2.6% | +0.2% | -2.9% | -2.3% | -3.5% | +4.2% | — |
| Oct 30, 2025 | BMO | 0.38 | 0.72 | +89.5% | 25.24 | +18.9% | +15.4% | +0.8% | +6.2% | +2.6% | +0.2% | — |
| Jul 31, 2025 | BMO | 0.26 | 0.51 | +96.2% | 17.40 | +19.9% | +16.1% | +4.2% | +0.8% | +2.7% | +0.9% | — |
| Apr 24, 2025 | BMO | 0.22 | 0.41 | +86.4% | 9.45 | +10.1% | +13.9% | +7.4% | +0.1% | +1.6% | -2.0% | — |
| Feb 20, 2025 | BMO | 0.32 | 0.32 | +0.0% | 10.91 | -17.7% | -17.6% | -6.0% | -2.4% | +0.1% | +3.9% | — |
| Oct 24, 2024 | BMO | 0.31 | 0.54 | +74.2% | 8.56 | +6.5% | +2.5% | +2.6% | -0.9% | +2.7% | +1.5% | — |
| Jul 25, 2024 | BMO | 0.40 | 0.44 | +10.0% | 10.88 | +16.5% | +20.3% | -2.3% | +2.0% | +4.7% | +0.7% | — |
| Apr 25, 2024 | BMO | 0.42 | 0.37 | -11.9% | 18.81 | -4.6% | -8.3% | +1.9% | +2.0% | -2.1% | +0.4% | — |
| Feb 22, 2024 | BMO | 0.28 | 0.43 | +53.6% | 17.50 | +14.6% | +21.7% | -0.1% | +0.6% | +4.0% | -1.6% | — |
| Nov 9, 2023 | BMO | 0.30 | 0.34 | +13.3% | 19.30 | -6.7% | -5.5% | -12.5% | -1.5% | +11.1% | +1.8% | — |
| Jul 27, 2023 | BMO | 0.22 | 0.39 | +77.3% | 24.39 | -1.6% | -3.6% | -3.1% | -2.4% | +2.3% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 18 | Barclays | Initiates | Overweight | $46 | $37.93 | $38.55 | +1.6% | +1.0% | — | — | — | — |
| Jan 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.44 | $36.22 | +2.2% | -2.5% | -1.6% | -1.1% | -2.2% | -1.1% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $29.13 | $29.68 | +1.9% | +0.8% | +6.2% | +2.6% | +0.2% | -0.6% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.24 | $30.00 | +18.9% | +15.4% | +0.8% | +6.2% | +2.6% | +0.2% |
| Aug 27 | Craig-Hallum | Maintains | Buy → Buy | — | $24.46 | $24.90 | +1.8% | -0.4% | -2.0% | +1.7% | +1.3% | +0.3% |
| Jun 30 | Craig-Hallum | Maintains | Buy → Buy | — | $13.95 | $14.19 | +1.7% | +5.7% | -0.5% | +5.0% | +0.1% | +0.9% |
| Mar 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.01 | $9.80 | -2.1% | -1.2% | -1.9% | -1.9% | +2.6% | -0.1% |
| Oct 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.77 | $9.16 | +4.4% | +2.6% | -0.9% | +2.7% | +1.5% | -3.1% |
| Oct 11 | Craig-Hallum | Maintains | Buy → Buy | — | $7.98 | $7.63 | -4.4% | -6.5% | +5.9% | +1.3% | +1.8% | +5.5% |
| Oct 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.98 | $7.63 | -4.4% | -6.5% | +5.9% | +1.3% | +1.8% | +5.5% |
| Sep 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.62 | $9.72 | +1.0% | +2.9% | -3.6% | -0.3% | +2.7% | -0.9% |
| Jul 10 | Craig-Hallum | Maintains | Buy → Buy | — | $10.19 | $9.90 | -2.8% | +3.1% | +7.8% | -4.3% | -4.1% | -0.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Heidbreder ChristianOff | Chief Scientific Officer | Sell | 18,586 | $38.06 | $707K | 227,923 | -0.21% | — |
| Jun 8, 2026 | Preblick RyanOff | Chief Financial Officer | Sell | 36,000 | $37.70 | $1.4M | 284,751 | +0.10% | -0.21% |
8-K · 8.01
!! High
Indivior Pharmaceuticals Inc -- 8-K 8.01: Material Event / Announcement
Indivior Pharmaceuticals disclosed a material event in an 8-K filing, though the specific announcement details are contained in the attached press release exhibit.
May 4
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
INDV secured a $75 million financing agreement, providing crucial capital for operations and growth that should strengthen its balance sheet and reduce near-term liquidity concerns for investors.
Mar 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Indivior increased debt financing by $50M and granted a $50M overallotment option, suggesting strong investor demand but raising leverage concerns for shareholders.
Mar 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Indivior is raising up to $260 million in convertible debt maturing 2031, diluting existing shareholders but providing liquidity and refinancing flexibility.
Mar 12
8-K
Indivior Pharmaceuticals, Inc. -- 8-K Filing
Indivior reported Q4 and full-year 2025 financial results with a business update, providing investors insight into the pharmaceutical company's recent operational performance and forward guidance.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Portfolio Management Llc | 7,891,819 | $241M | New | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 5,586,576 | $170M | New | Mar 2026 |
| 3 | Millennium Management | 4,595,535 | $140M | New | Mar 2026 |
| 4 | Citadel Advisors Llc | 3,574,044 | $109M | New | Mar 2026 |
| 5 | Deerfield Management Company, L.p. | 3,097,790 | $94M | New | Mar 2026 |
| 6 | Arrowstreet Capital, Limited Partnership | 2,323,264 | $71M | New | Mar 2026 |
| 7 | Ubs Group Ag | 2,192,264 | $67M | New | Mar 2026 |
| 8 | Healthcare Of Ontario Pension Plan Trust Fund | 1,835,100 | $56M | New | Mar 2026 |
| 9 | Barclays Plc | 1,745,751 | $53M | New | Mar 2026 |
| 10 | Invesco Ltd. | 1,561,763 | $48M | New | Mar 2026 |
| 11 | Acadian Asset Management Llc | 1,391,612 | $42M | New | Mar 2026 |
| 12 | Soleus Capital Management, L.p. | 1,274,000 | $39M | New | Mar 2026 |
| 13 | Northern Trust Corp | 1,161,403 | $35M | New | Mar 2026 |
| 14 | Nuveen, Llc | 930,911 | $28M | New | Mar 2026 |
| 15 | Bnp Paribas Financial Markets | 828,891 | $25M | New | Mar 2026 |
| 16 | Melqart Asset Management (Uk) Ltd | 684,320 | $21M | New | Mar 2026 |
| 17 | Bank Of New York Mellon Corp | 682,777 | $21M | New | Mar 2026 |
| 18 | Bank Of America Corp /de/ | 667,132 | $20M | New | Mar 2026 |
| 19 | Op Asset Management Ltd | 535,060 | $18M | New | Mar 2026 |
| 20 | Fmr Llc | 527,714 | $16M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$4.78B
Enterprise Value
$5.00B
P/E (TTM)
23.35x
Forward P/E
12.24x
PEG Ratio
0.00x
P/B
—
P/S
3.96x
P/FCF
-52.71x
EV/EBITDA
16.44x
Shares Out
128.0M
Financials (TTM)
Revenue
$1.24B
Net Income
$210.0M
EBITDA
$304.0M
Free Cash Flow
-$93.0M
Op Cash Flow
-$27.0M
EPS Basic
$1.68
EPS Diluted
$1.64
EPS Forward
$3.13
Gross Margin
80.2%
Op Margin
21.1%
Net Margin
17.0%
Balance Sheet
Total Assets
$1.20B
Total Liab.
$1.30B
Total Equity
-$98.0M
Cash
$195.0M
LT Debt
$290.0M
Book Value/Sh
$-0.78
Debt/Equity
-3.58x
Current Ratio
0.71
Quick Ratio
0.55
Returns & Growth
ROE
-214.3%
ROA
17.5%
ROIC
70.0%
Rev Growth YoY
+4.3%
EPS Growth YoY
+11025.8%
Price Returns
2W
-4.8%
1M
-2.1%
3M
+10.1%
6M
+7.2%
12M
+180.1%
Technicals
52W High
$41.00
52W Low
$13.45
50d MA
$36.20
200d MA
$32.03
RSI (14)
63.00
ATR (14)
$1.30
Beta
1.21
Avg Volume
1.9M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$43.75
High
$50.00
Low
$36.00
Median
$44.50
Data updated apr 25, 2026 3:33pm
· Source: financialmodelingprep.com